<DOC>
	<DOCNO>NCT00777036</DOCNO>
	<brief_summary>The purpose study determine whether dasatinib safe effective child adolescent newly diagnose chronic myeloid leukemia ( CML ) , child Ph+ acute lymphoblastic leukemia ( ALL ) , accelerate blast phase CML relapse imatinib resistant intolerant imatinib . The side effect oral investigational drug child adolescent evaluate</brief_summary>
	<brief_title>A Phase II Study Dasatinib Children Adolescents With Newly Diagnosed Chronic Phase CML With Ph+ Leukemias Resistant Intolerant Imatinib</brief_title>
	<detailed_description>Cohort 2 close enrollment</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . CPCML prove resistant intolerant imatinib ( cohort # 1 ) Ph+ ALL , APCML , BPCML resistant intolerant relapse imatinib therapy ( cohort # 2 ) Newly diagnose , treatment naive CPCML ( cohort # 3 ) Lansky Karnofsky scale &gt; 50 Life expectancy â‰¥12 week Adequate hepatic renal function Written inform consent Eligibility potentiallycurative therapy include hematopoietic stemcell transplantation Symptomatic CNS involvement ( sign symptom cause leptomeningeal disease ) Isolated extramedullary disease Prior therapy Dasatinib</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Leukemia , Pediatric</keyword>
</DOC>